Mario Saltarelli, M.D., Ph.D., Senior Vice
President, Early Development and Neurology, Vertex
Jack Hoppin, Ph.D., Co-Founder & Chief
Executive Officer, Invicro
Sue O’Connor, B.Sc. (Hons), Ph.D.,
Vice President, Neuroscience Research, Bionomics
BIOASIS TECHNOLOGIES INC. (TSX.V:BTI;
OTCQB:BIOAF), a biopharmaceutical company developing xB3 TM, a
proprietary platform technology for the delivery of therapeutics
across the blood-brain barrier (BBB) and the treatment of CNS
disorders, including brain cancers and neurodegenerative diseases,
today announced the addition of Mario Saltarelli, M.D., Ph.D.,
senior vice president of early development and neurology at Vertex
Pharmaceuticals Incorporated, Jack Hoppin, Ph.D., co-founder and
chief executive officer at Invicro, and Sue O’Connor, B.Sc.
(Hons), Ph.D., vice president of neuroscience research at
Bionomics, to its scientific advisory board (SAB). The Bioasis SAB
is chaired by Professor John H. Krystal, M.D., chair of the
department of psychiatry and professor of neuroscience, Yale
University School of Medicine and chief of psychiatry, Yale-New
Haven Hospital. Additional Bioasis SAB members include Jeffrey L.
Cummings, M.D. and John P. Wikswo, Jr., Ph.D. The first Bioasis SAB
will convene on Fri., July 6, 2018.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20180612005541/en/
Mario Saltarelli, M.D., Ph.D., Senior
Vice President, Early Development & Neurology, Vertex
Pharmaceuticals Incorporated (Photo: Business Wire)
"I’ve been fortunate to have worked with Mario while at Abbott
and with Jack since he founded Invicro in 2008. I first met Sue at
Bionomics in my role as head of neuroscience business development
at Bristol Myers Squibb. On behalf of Professor John Krystal and I,
we are delighted to welcome Mario, Sue and Jack to the Bioasis
SAB,” said Mark Day, Ph.D., president and chief executive officer,
Bioasis.
"Mario has more than two decades of exceptional industry
leadership,” said Dr. Day. "Mario’s extensive medical science,
global clinical drug development, scientific and regulatory
clinical program design expertise in diseases related to the
central nervous system will be tremendously valuable as we advance
our in-house programs.”
“The Bioasis team is truly focused - everything they do is
dedicated to bringing new medicines to patients suffering from
neurological diseases as quickly as possible,” said Dr. Saltarelli.
“I am eager to work with this SAB to guide the team’s pre-clinical
models to help predict how the medicines will perform in patients
for a higher probability of success.”
“Jack’s translational science and drug development expertise,
specifically in translatable quantitative biomarker strategies for
diseases related to the central nervous system, is directly aligned
with our focus on delivering medicines across the blood-brain
barrier to treat neurological diseases and disorders,” said Dr.
Day. “As we move closer to the next phases of our in-house
development programs, we look forward to his insightful
contributions with a key focus on imaging bioinformatics in drug
development and discovery in the areas of brain cancers and
neurodegeneration, to the Bioasis SAB.”
"Bioasis has a unique and versatile approach to delivering
therapeutics across the blood-brain barrier and into the brain, a
solution to a problem that has blocked development of effective
treatments for neurological disorders," said Dr. Hoppin. “I am
thrilled to work with Mark again and I look forward to contributing
to the company's focus on translational medicine and biomarker
strategies to advance its clinical pipeline.”
“Sue is an exceptional scientist and has been a major
contributor to the translation of preclinical discovery programs to
clinical stage,” said Dr. Day. “Sue brings extensive, relevant
discovery and clinical development expertise to this SAB and shares
our dedication to discover and develop effective therapies for
brain-related diseases. Moreover, Sue and her colleagues have built
a robust preclinical and clinical portfolio that I consider to be a
best-in-class CNS pipeline.”
“I am truly excited to join the Bioasis SAB and to be involved
with this innovative company with such tremendous potential,” said
Dr. O’Connor. “I share the team's conviction and approach to
tackle these important clinical programs in brain cancer and
neurodegenerative diseases. I am all in to take part in the
strategic development for this platform to make new, effective
medicines to treat serious unmet medical needs in CNS disorders and
diseases.”
About Mario Saltarelli, M.D., Ph.D.
Dr. Mario Saltarelli is a senior vice president of early
development and neurology at Vertex Pharmaceuticals Incorporated.
Vertex (NASDAQ: VRTX) discovered and developed the
first medicines to treat the underlying cause of cystic
fibrosis (CF), a rare, life-threatening genetic disease. Dr.
Saltarelli leads Vertex’s early development activities, including
translational medicine, clinical pharmacology, clinical biomarkers
and neurology. For more than 20 years, Dr. Saltarelli has been
focused on defining, building and successfully advancing
development pipelines through the application of advanced
translational paradigms in the biomedical and pharmaceutical
sectors.
Prior to joining Vertex, Dr. Saltarelli served as chief medical
officer at Annexon Biosciences, Inc. and served as the chief
science officer and senior vice president of Mallinckrodt. Dr.
Saltarelli served as senior vice president of clinical development
and medical affairs at Shire. His diverse background spans more
than three decades across medical science, clinical drug
development and the scientific and regulatory aspects of clinical
program design. He joined Shire from Abbott Laboratories where he
served as the divisional vice president directly accountable for
all aspects of clinical development, medical affairs and
development strategy for global neuroscience and anesthesia
products. Prior to that, he spent seven years at Pfizer global
research and development in Connecticut, ultimately as an executive
director, head of the CNS early clinical development group. He
served as director of MindImmune Therapeutics. He served for four
years as an assistant professor of neurology at Emory University
School of Medicine.
Dr. Saltarelli earned his bachelor of science degree in
psychology from the University of Illinois at Urbana-Champaign, a
doctor of medicine degree and a doctor of philosophy degree in
neuropharmacology from The Johns Hopkins University School of
Medicine. He was an intern in internal medicine at the University
of Maryland Medical Center and completed neurology residency at The
Johns Hopkins Hospital.
About Jack Hoppin, Ph.D.
Dr. Jack Hoppin is the co-founder and chief executive officer of
Invicro. Invicro, LLC was founded with the mission of improving the
role and function of imaging in translational drug discovery and
development across all therapeutic areas. Invicro’s
multi-disciplinary team provides a full range of image informatics,
engineering and operational services. Prior to co-founding
Invicro in 2008, Dr. Hoppin served as the vice president of imaging
systems at Bioscan, Inc. Dr. Hoppin, a thought-leader in the
molecular imaging research and drug development community, brings
15+ years in experience in the design, development and
commercialization of pre-clinical instrumentation, analytical
software and imaging-based assays. As an active member of the
imaging community, Dr. Hoppin recently serving on the World
Molecular Imaging Society Board of Trustees. He is also a member of
the Society of Nuclear Medicine CMIIT Industry Council and the
Harvard Catalyst Faculty.
Dr. Hoppin earned his bachelor of science degree in mathematics
with a minor in physics from the College of the Holy Cross in
Worcester, Mass., USA, and his master of science degree and doctor
of philosophy degree in applied mathematics from the University of
Arizona in Tucson, Ariz., USA. Dr. Hoppin worked as an Alexander
von Humboldt post-doctoral fellow in medical physics at the
Research Center in Jülich, Germany.
About Sue O’Connor, B.Sc. (Hons), Ph.D.
Dr. Sue O'Connor is currently vice president of neuroscience
research at Bionomics Ltd. in Adelaide, Australia. Bionomics (ASX:
BNO) is a global, clinical stage biopharmaceutical company
leveraging its proprietary platform technologies to discover and
develop a deep pipeline of best in class, novel drug candidates
targeting ion channels. Dr. O’Connor joined Bionomics in 2003 as a
member of the drug discovery team before her appointment as senior
director of central nervous system research and development. Her
role at Bionomics has included a high level of involvement with the
identification of BNC210, a drug candidate with considerable
potential as a new treatment for anxiety disorders and a
collaboration with Merck & Co on a discovery-phase pain
program. Dr. O’Connor’s current focus is the development of new
drugs to treat cognitive impairment associated with several disease
states. One of these programs was partnered with Merck &
Co in 2014 and is now in early clinical development. Previously she
entered the biotechnology sector working on drug development
projects in the department of gastroenterology at Flinders Medical
Centre. During this time, Dr. O’Connor’s interest in
neuro-psychopharmacology and the development of drugs for the
treatment of psychiatric disorders was formed.
Dr. O’Connor earned her doctor of philosophy degree in molecular
genetics from the University of Adelaide, Australia and completed
her post-doctoral research at the Hanson Institute in Adelaide,
Australia.
About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company
developing xB3, a proprietary platform technology for the delivery
of therapeutics across the blood-brain barrier (BBB) and the
treatment of CNS disorders, including brain cancers and
neurodegenerative diseases. The delivery of therapeutics across the
BBB represents the final frontier in treating neurological
disorders. The in-house development programs at Bioasis are
designed to develop symptomatic and disease-modifying treatments
for brain-related diseases and disorders. The company maintains
headquarters in Richmond, BC, Canada with offices in Guilford,
Conn., United States. Bioasis trades on the TSX Venture Exchange
under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.”
For more information about the company please
visit www.bioasis.ca or www.bioasis.us.
Forward Looking Statements
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
“believe”, “may”, “plan”, “will”, “estimate”, “continue”,
“anticipate”, “intend”, “expect” and similar expressions. Such
forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be
materially different from any future results, events or
developments express or implied by such forward-looking statements
or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital
requirements, risk associated with the completion of clinical
trials and obtaining regulatory approval to market our products,
the ability to protect our intellectual property, dependence on
collaborative partners and the prospects for negotiating additional
corporate collaborations or licensing arrangements and their
timing. Specifically, certain risks and uncertainties that could
cause such actual events or results expressed or implied by such
forward-looking statements and information to differ materially
from any future events or results expressed or implied by such
statements and information include, but are not limited to, the
risks and uncertainties that: products that we develop may not
succeed in preclinical or clinical trials, or future products in
our targeted corporate objectives; our future operating results are
uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing
additional corporate collaborations or licensing arrangements; we
may not be able to establish marketing and the costs of launching
our products may be greater than anticipated; we have no experience
in commercial manufacturing; we may face unknown risks related to
intellectual property matters; we face increased competition from
pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Canadian securities
regulatory authorities at www.sedar.com. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward- looking statements and information to
reflect subsequent events or circumstances, except as required by
law.
“Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180612005541/en/
Media & Investor Relations:Bioasis Technologies,
Inc.Catherine London, +1 917 763 2709Catherine@bioasis.us
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Mar 2023 to Mar 2024